3 stocks that soared stupendously this week  6-13-14
Upcoming SlideShare
Loading in...5

Like this? Share it with your network


3 stocks that soared stupendously this week 6-13-14



3 of this week's biggest health-care stocks

3 of this week's biggest health-care stocks



Total Views
Views on SlideShare
Embed Views



11 Embeds 5,265

http://www.fool.com 5154
http://m.fool.com 35
http://barchartjson.websol.barchart.com 31
http://www.barchart.com 29
http://translate.googleusercontent.com 9
https://translate.googleusercontent.com 2
http://www.mysanantonio.com 1
http://www.greenwichtime.com 1
http://www.seattlepi.com 1
http://www.slideee.com 1
http://mockup.www.fool.com 1


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849

3 stocks that soared stupendously this week 6-13-14 Presentation Transcript

  • 1. 3 Stocks That Soared Stupendously This Week
  • 2. Plenty of health-care stocks saw big upward moves this week. These three stocks, though, really blew the market away.
  • 3. Shares of the biopharmaceutical firm skyrocketed 226% higher for the week. Idenix Pharmaceuticals (Nasdaq:IDIX) Source: Yahoo! Finance
  • 4. • Merck (NYSE:MRK) announced a buyout of Idenix for $3.85 billion • The price tag of $24.50 per share raised lots of eyebrows, since it reflected a nearly 240% premium over Idenix’s closing value prior to the announcement • Idenix’s hepatitis C pipeline proved enticing to Merck, which has a couple of hep-C drugs in development of its own • The deal is expected be finalized in the third quarter this year Why Idenix shares ignited
  • 5. Shares of the drug maker specializing in hepatitis C and antibacterial therapies surged 128% this week. Achillion Pharmaceuticals (Nasdaq:ACHN) Source: Yahoo! Finance
  • 6. • Achillion also scored big from the Merck buyout of Idenix • The big price tag paid for Idenix raised speculation that another big player could make a bid for Achillion to gain access to its hepatitis C drug, ACH-3422 • Achillion’s other big news helped tremendously as well – a decision by the FDA to remove a clinical hold on testing of hep-C drug sovaprevir • In lesser news, Achillion announced the start of a trial of ACH-3422, another hepatitis C drug Why Achillion shares advanced big-time
  • 7. Shares of the clinical-stage biopharmaceutical company soared 43% higher this week. Geron Corporation (Nasdaq:GERN) Source: Yahoo! Finance
  • 8. • Like Achillion, Geron benefited from an FDA decision to remove a clinical hold • In this case, testing will be able to resume for Geron’s imetelstat, which targets treatment of myelofibrosis • The FDA placed a partial clinical old on testing of the drug in March because of worries about liver damage in patients participating in studies • Clinical holds remain in place for studies of imetelstat focusing on treatment of thrombocythemia and multiple myeoloma Why Geron shares jumped
  • 9. • Idenix has enjoyed its huge moment, but don’t expect shares to climb much more • Achillion could keep moving up, but there’s a real possibility that this week’s massive move could reflect some over-exuberance • The nod for best pick to keep the winning ways rolling goes to Geron – if the FDA decides to also lift clinical holds for company-sponsored trials of imetelstat • That remains a big “if” at this point, but Geron could get another big boost should a positive decision occur Best pick to keep soaring?
  • 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!